Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

326 to 339 of 339 results

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

German IQWiG finds mixed added benefits for Eliquis

02-04-2012

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

"NICE" news for Novartis CML drugs, but not for Bristol-Myers

22-03-2012

In final draft guidance issued this morning, UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

New Zealand approves Effient listing for clopidogrel-allergic patients

19-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

Esbriet offers additional benefit, says German G-BA

16-03-2012

USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Positive NICE news for Gilenya for MS and Incivo for hep C

16-03-2012

There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

NICE recommends NHS use of Pradaxa

15-03-2012

In final guidance published today (March 15), the UK drug watchdog the National Institute of Health and…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

EU Commission medicines availability proposals viewed by Finnish pharma

13-03-2012

The amendments envisaged in the European Union legislation could accelerate the price and reimbursability…

EuropePharmaceuticalPricingRegulation

German pharma criticizes new AMNOG vetting procedure

13-03-2012

Until recently, pharmaceutical companies could set prices for new drugs in Germany. But now their "monopoly…

EuropePharmaceuticalPricingRegulation

UK NICE asks Bayer for Xarelto cost-effectiveness data

13-03-2012

UK health care price watchdog the National Institute for Health and Clinical Excellence (NICE), which…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

NICE backs Merck & Co hep C drug Victrelis

09-03-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 9)…

Anti-viralsEuropeMerck & CoPharmaceuticalPricingRegulationVictrelis

New Zealand to fund new cancer drugs Tykerb and Votrient

05-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, says it is funding two new targeted cancer…

Asia-PacificGlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTykerbVotrient

326 to 339 of 339 results

COMPANY SPOTLIGHT

Menarini

Back to top